One Page to Access
Information on Drug Access in the Brazilian and Latin American Market.

The reality of the journey of those living with rare diseases in Brazil.
In February, more precisely on the 28th, World Rare Disease Day is celebrated. The event was created in 2008 by the European Organization for Rare Diseases (Eurordis) to raise awareness of governments, health professionals, and the population about the existence and...
National Supplementary Health Agency
ANS is the acronym for National Supplementary Health Agency, an autarchy created to implement regulation of the private health market in the country. Linked to the Ministry of Health, ANS was created by Law 9.961/2000, with the aim of “Promoting defense of the public interest in supplementary health care, regulating sectoral operators – including terms of their relations with generation and consumers – and contributing for the development of health actions in the country.”
Learn more about CONITEC
The National Commission for the Incorporation of Technologies in the Unified Health System (CONITEC) is the body responsible for assisting the Ministry of Health in the process of inclusion, exclusion, or modification of health technologies in the SUS and also in the elaboration or revision of Clinical Protocols and Guidelines Therapeutics (PCDT).
Brazilian Medicines Market Regulation Chamber (CMED)
Created in 2003, the Brazilian Medicines Market Regulation Chamber (CMED) is the inter-ministerial body responsible for the economic regulation of the medicines market in Brazil.
Learn more about ANVISA:
Created by law nº 9,782 of January 26, 1999, the National Health Surveillance Agency (ANVISA) is an autarchy under a special regime, which has its headquarters and jurisdiction in the Federal District and is present throughout the Brazilian territory.
Growth of Latin America in relation to the Global market and the various opportunities that the Brazilian market presents for the rare disease and high complexity segment.
In this issue, continuing the theme, we will delve a little deeper into the numbers referring to the market
of “non-retail” market.
Does your company have a strategy for the Latin American market?
Latin America grew twice as much as the global drug market in 2020. The market has the largest growth opportunity in the pharmaceutical industry in the world.